1.
Changing costs of metastatic non small cell lung cancer in the Netherlands
2.
Noacs replace VKA as preferred oral anticoagulant among new patients
COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN